Random forest identifies experimentally active antichlamydial compounds
Source check: Source checked. Not independent scientific confirmation.
Finding: A random-forest model trained on measured compound activity screened ChEMBL and guided selection of 25 commercially available molecules for testing. Twelve showed antichlamydial activity below 10 micromolar and three were submicromolar in cell-culture assays, with the top three also checked by quantitative PCR. This entry covers the AI-selected subset; the larger experimental-screening hit set and FabH mechanism result are separate parts of the paper, and clinical efficacy is not established.
Technology: Random-forest classifier
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
- AI contribution
- A random forest used molecular descriptors to rank compounds, followed by chemical-similarity, availability and human selection filters.
- Test and result
- Twelve of 25 AI-selected compounds were active below 10 micromolar in cell-culture assays; the top three were also checked by quantitative PCR.
- Limitation / still unknown
- Clinical efficacy and safety are not established. The authors warn that the simple classifier may overfit related scaffolds and may not generalize to chemically distant molecules.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.1371/journal.pbio.3003123 · https://pmc.ncbi.nlm.nih.gov/articles/PMC12040169/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary full article Methods, result-specific experiments, discussion, affiliations and journal publication metadata; no independent replication performed..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.